clinical AI

Cleveland Clinic CIO Sarah Hatchett talks about how the health system is leveraging AI for use cases like clinical documentation, coding and sepsis detection to boost productivity for clinical and non-clinical staff.

Hal Wolf, HIMSS CEO, spotlights upcoming HIMSS26 presentations from Taiwan's China Medical University Hospital and South Korea's Samsung Medical Center, which will discuss AI-driven transformation and digital maturity.

Virginia Halsey of FDB explains how Model Context Protocols set limits for AI models so they defer to human clinical judgment rather than guessing at answers. This prevents hallucinations that can impact patient safety.

Shlomi Madar, CEO of SpotitEarly, discusses the company's noninvasive test using a breath sample, which is analyzed by specially trained dogs capable of identifying unique cancer-related scent signatures combined with AI technology.

Abhinav Shashank, Innovaccer CEO and cofounder, highlights the company's recently published manifesto, Autonomous Healthcare, and previews his upcoming HIMSS26 panel with other unicorn founders on tackling challenges in health tech.

CEO of Lirio, Marten den Haring, explains how the company uses its proprietary Large Behavior Model to understand a person’s health behaviors, motivations and decision-making patterns to drive personalized patient engagement in healthcare.

As medical practices seek to implement agentic AI, Michael Clark, OnPoint Healthcare Partners president, recommends constant oversight to ensure agents' work is repeatable, auditable and traceable by a clinical advisory team.

AION Labs CEO, Mati Gill, discusses the company’s extensive backing from pharma and tech giants to build AI startups, and how AION is looking beyond AI to explore quantum technologies for research and development in drug discovery.

Eric Jimenez, Artesia General Hospital CIO, says the hospital first deployed AI to protect its network after a cyber incident. It expanded to ambient listening and is now seeking to use AI for clinical applications.

Michael Abrams of Numerof and Associates says that oversight for AI used in mental health care should mirror that of pharmaceuticals, with clear standards, safety testing and ongoing monitoring.